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Gastric Carcinomas in Young (Younger than 40 Years)
Chinese Patients
Clinicopathology, Family History, and Postresection Survival
Fan Zhou, PhD, Jiong Shi, PhD, Cheng Fang, PhD, Xiaoping Zou, MD, and Qin Huang, MD
Abstract: Little is known about clinicopathological characteristics of
gastric carcinoma (GC) in young (40 years) Chinese patients. We
aimed in this study to analyze those features along with family history
and prognostic factors after resection.
We retrospectively reviewed all 4671 GC resections (surgical and
endoscopic) performed at our center from 2004 to 2014 and identified
152 (3.2%) consecutive young patients. Patient demographics, clinical
results, family history, and endoscopic-pathological findings were
analyzed along with the older (>41 years) GC controls recruited in
the same study period. Clinicopathological factors related to postresec-
tion outcomes were assessed statistically.
The trend of GC resections in young patients was not changed over
the study period. Compared to old GCs, the young GC cohort was
predominant in women, positive family history, middle gastric location,
the diffuse histology type, shorter duration of symptoms, and advanced
stage (pIIIþpIV, 53.3%). Radical resection was carried out in 90.1%
(n¼ 137) with a better 5-year survival rate (70.3%) than palliative
surgery (0%, n¼ 15). There was no significant difference in clinico-
pathological characteristics between familial GC (FGC, n¼ 38) and
sporadic GC (SGC, n¼ 114) groups. Very young patients ( 30 years,
n¼ 38) showed lower Helicobacter pylori (Hp) infection and signifi-
cantly higher perineural invasion rates, compared to older (31–40 years)
patients. Hp infection was more commonly seen in the Lauren’s
intestinal type and early pT stages (T1þT2). Independent prognostic
factors for worse outcomes included higher serum CA 72–4, CA 125
levels, positive resectionmargin, and stage pIII–pIV tumors. The 5-year
survival rate was significantly higher in patients with radical resection
than those without.
GCs in young Chinese patients were prevalent in women with
advanced stages but showed no significant differences in clinicopathol-
ogy between FGC and SGC groups. High serum CA 72–4 and CA 125
levels may help identify patients with worse outcomes. Radical resec-
tion improved postresection survival.
(Medicine 95(9):e2873)
Abbreviations: AJCC = American Joint Committee on Cancer,
EOGC = early-onset gastric cancer, FGC = familial gastric cancer,
GC = gastric carcinoma, SGC = sporadic gastric cancer.
INTRODUCTION
A t present, the incidence of gastric carcinoma (GC) hassteadily decreased worldwide due to effectiveHelicobacter
pylori (Hp) screening and treatment, as well as early detection
by upper endoscopy.1 However, GC remains the third leading
cause of cancer-related deaths in China.2,3 In general, GC
occurs primarily in elderly patients aged 60 years; only
2.7% to 15% of patients are 40 years old,4–6 as the
early-onset gastric cancer (EOGC).7 Previous studies show that
EOGCs occur mainly in female patients with the histology
diffuse type (Lauren’s classification), advanced tumor stage,
and high incurable rates.4,8,9
Although detailed pathogenesis mechanisms of GC remain
elusive, environmental factors combined with specific genetic
alterations in the vulnerable population play critical roles in GC
tumorigenesis.10–12 Because EOGC patients expose to environ-
mental toxins much lesser than older patients, hereditary factors
may be of more importance in EOGC tumorigenesis.13 Indeed,
10% to 25% of EOGC patients have a positive family
history,6,9,14,15 some of whom have hereditary GC syndromes,
such as hereditary diffuseGCwith 25% to50%of cases harboring
germline CDH1 gene mutations. However, the CDH1 gene
mutation rate differs considerably between high- and low-
incidence regions in the world. In a Japanese study on CDH1
gene mutations in 13 familial gastric cancer (FGC) families,16
only 1 missense somatic mutation was identified. Most Chinese
studies also revealed no truncating germline CDH1 gene
mutations in FGC families or EODGC patients,17–19 a feature
different from that reported in Europeans.20,21
The reports on prognosis of EOGC patients after resection
also show conflicting results.5,8,9,22–25 Some studies demon-
strate an unfavorable prognosis in very young (<30 years) GC
patients, which was interpreted as a result of delayed diagnosis
and rapid disease progression,5,25 whereas others report no
significant differences in survival between the very young
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and older GC patient groups.9,22–24 Some investigators have
even described better survival rates in EOGC patients, com-
pared to older GC patients.8 However, few studies have focused
on clinicopathologic features of young Chinese GC patients and
those with a family history of GC in the first- or second-degree
relatives. The aims of this study were to characterize clinico-
pathology of EOGC, compared to old (>41 years) GCs, elu-
cidate prognostic factors, especially in familial EOGC patients,
and compare differences between very young (30 years) and
older (31–40 years) EOGC patients groups in a homogeneous
Chinese population.
METHODS
Patients
We searched GC resection cases in the electronic pathol-
ogy databank stored in the Department of Pathology of the
Nanjing Drum Tower Hospital over the period between January
2004 and December 2014. All pathology reports were retrieved
and reviewed by 2 experienced pathologists. Inclusion criteria
for the EOGC study were: (1) surgical or endoscopic GC
resection, (2) patient age 40 years. Exclusion criteria con-
sisted of: (1) GC diagnosed by endoscopic biopsy without
resection, (2) no archival tissue blocks available for recuts,
and (3) the patient lost to follow-up. The control group consisted
of 250 older (>41 years) GC patients recruited from the same
study period. Consent for GC resection and research was
obtained from each patient before the resection procedure
was taken place. The study protocol was approved by
the Medical Ethics Committee of the Nanjing Drum Tower
Hospital.
Data
Clinical features of each patient, extracted from the
medical record, included demographics, symptoms and
durations, body mass index (BMI), endoscopic findings (tumor
site, macroscopic pattern defined by the WHO classification),26
adjuvant therapy, tumor recurrence, and Hp infection status
(determined by the rapid urease test). Grossly, early GC was
categorized as protruded (type 0–I), superficially elevated (type
0–IIa), superficially flat (type 0–IIb), superficially depressed
(type 0–IIc), and excavated (type 0–III) patterns, whereas
advanced GC showed 4 patterns, including polypoid (type I),
fungating (type II), ulcerated (type III), and flat infiltrative
feature (type IV). Tabulated were laboratory test results on
serum levels of albumin (normal range: 35–50 g/L), CA 72–4
(normal range: 0–6.9 U/mL), CA 125 (normal range: 0–30.2 U/
mL), CA 19–9 (normal range: 0–39 U/mL), CA 242 (normal
range: 0–15 U/mL), CEA (normal range: 0–10 ng/mL), and
AFP (normal range: 0–10 ng/mL). Also analyzed were surgical
resection methods, operative morbidity, and pathological details
such as tumor size and 4 primary tumor locations: (1) proximal,
including gastroesophageal junction and proximal third of the
stomach, (2) middle (corpus), and (3) distal stomach, from the
incidura, antrum to pylorus, and (4) whole stomach. Pathology
features assessed were Lauren’s classification, the WHO tumor
histology type, WHO tumor differentiation, tumor stage (based
on the 7th edition of the American Joint Committee on Cancer
[AJCC7]),27 lymphovascular invasion (LVI), perineural inva-
sion (PNI) (defined as the process of neoplastic invasion of
nerves),28 and resection margin status. All selected patients
were interviewed and followed-up through telephone or home
visit by a trained gastroenterologist for detailed family history
Surgical resection (n=152) Endoscopic resection (n=0) 
Study cohort GC patients (n=152) 
Included in this study for further analysis 
Palliative (n=15)   
Curative-intend 
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gastrectomy 
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gastrectom
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FIGURE 1. Flowchart showing early-onset gastric cancer study cohort and treatment modalities.
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(living status of first- and second-degree relatives of the pro-
band). According to the FGC diagnostic guideline of the Nether-
land Research Group,29 the criteria for FGC included GC in 2 or
more first- or second-degree relatives, with at least 1 having GC
diagnosed before the age of 50 years or GC in 3 or more first- or
second-degree relatives, independent of age. GC patients with-
out a positive family history were grouped as spontaneous GC
(SGC).
Statistical Analysis
Categorical variables were compared with Pearson’s Chi-
square (x2) test or Fisher’s exact test; continuous variables were
evaluated by Student’s t test or Mann–Whitney U test. Corre-
lations between various factors and Hp infection status were
assessed by univariate and multivariate logistic regression
analyses. Patient survival was estimated with the Kaplan–Meier
method and a log-rank test. Postresection overall survival was
analyzed by univariate and multivariate Cox proportional
hazards regression models. Variables found to be statistically
significant by the univariate analysis were further scrutinized
backward stepwise by the multivariate analysis, in which the
least significant variable was excluded sequentially. Indepen-
dent risk factors were presented as the hazard ratio (HR) with
95% confidence interval (CI). All 2-tailed P values of <0.05
were considered statistically significant. All statistical analyses
were performed using SPSS Statistics Version 22 (SPSS Inc,
Chicago, IL).
RESULTS
Demographics and Baseline Characteristics
Among 175 EOGC patients with the median age of 33
years (range: 17–40), 23 patients were lost to follow-up or did
not have a detailed family history and thus excluded from the
analysis (Figure 1). A total of 152 young patients and 250 old
patients were eligible for the study (Table 1). The mean follow-
up time for surviving patients was 38.1 months. There was no
significant change in the trend in EOGC resections observed
over the 11-year study period (Figure 2A). The overall male-to-
female ratio was 0.53:1, which was significantly lower than that
of old patients (P< 0.01, Table 1). The female-to-male patient
ratio increased dramatically in the 31 to 40 years groups,
compared to that of very young ( 30 years) patient group
(Figure 2B).
Clinical Findings
Overall, the symptom at diagnosis of all patients was
nonspecific (Table 1). Only 25.7% EOGC and 19.2% old GC
patients showed alarming clinical presentations, such as severe
dysphagia, considerable gastrointestinal bleeding, and vomit-
ing. Most young patients (82.2%) had a short duration of
symptoms.
Upper Endoscopy
The most common EOGC location was in the distal
(49.3%) stomach, followed by the middle (37.5%). Only
5.3% of cases occurred in the proximal stomach (Table 1).
In contrast in old patients, GC tumors were significantly more
common in the proximal stomach (P< 0.01), but significantly
less frequent in the middle (P< 0.01), and similarly common in
the distal stomach (Table 1). Macroscopically in EOGCs, the
most common pattern was type III (43.4%), followed by type II
TABLE 1. Clinicopathologic Features of Early-Onset Gastric
Carcinoma in Chinese Patients (Younger than 40 Years of Age)
Versus Those in Patients 41 Years or Older
Features
Young Patients
(N¼ 152)
Old Patients
(N¼ 250) P
Age 33.7 5.54 62.9 10.4 <0.01
Gender <0.01
Male 53 (34.9%) 178 (71.2%)
Female 99 (65.1%) 72 (28.8%)
Positive familiar
gastric cancer
patients
38 (25.0%) 40 (16.0%) 0.027
Symptom at
diagnosis
Abdominal pain 73 (48.0%) 98 (39.2%) 0.083
Discomfort 37 (24.3%) 95 (38.0%) <0.01
Alarming features 39 (25.7%) 48 (19.2%) 0.127
Gastrointestinal
bleeding
19 (12.5%) 11 (4.4%)
Distant
metastasis
7 (4.6%) 5 (2.0%)
Vomiting 7 (4.6%) 17 (6.8%)
Dysphagia 6 (4.0%) 15 (6.0%)
Diarrhea 2 (1.3%) 1 (0.4%) 0.560
Discovered at
health check-up
1 (0.7%) 8 (3.2%) 0.162
Duration of
symptom
<0.01
<1 year 125 (82.2%) 142 (56.8%)
1 year 27 (17.8%) 108 (43.2%)
Tumor site
Proximal 8 (5.3%) 75 (30%) <0.01
Middle 57 (37.5%) 53 (21.2%) <0.01
Distal 75 (49.3%) 115 (46%) 0.515
Whole gastric 12 (7.9%) 7 (2.8%) 0.02
Macroscopic type
0 31 (20.4%) 57 (22.8%) 0.572
0–I 4 (2.6%) 10 (4.0%)
0–IIA 3 (2.0%) 9 (3.6%)
0–IIB 12 (7.9%) 14 (5.6%)
0–IIC 10 (6.6%) 14 (5.6%)
0–III 2 (1.3%) 10 (4%)
I 5 (3.3%) 35 (14.0%) <0.01
II 34 (22.4%) 63 (25.2%) 0.520
III 66 (43.4%) 70 (28%) <0.01
IV 16 (10.5%) 25 (10%) 0.866
Hp infection 70 (51.1%) 154 (61.6%) 0.045
Lauren’s
classification
Diffuse 112 (79.4%) 73 (29.2%) <0.01
Intestinal 13 (9.2%) 156 (62.4%) <0.01
Mixed 16 (11.3%) 21 (8.4%) 0.475
Clinical staging
0 (Tis) 0 12 (4.8%) <0.01y
IAþIB 39 (25.7) 129 (51.6%) <0.01
IIAþIIB 32 (21.1) 35 (14%) 0.066
III 66 (43.4) 52 (20.8%) <0.01
IV 15 (9.9) 22 (8.8%) 0.719

x2 test. y Fisher’s exact test.
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and type 0; the type I pattern was the least (3.3%) frequent, and
whole stomach involvement was found in 16 patients (10.5%).
In type 0 GCs, type IIB and IIC lesions were most common
(7.9% and 6.6%). In comparison in old GCs, the type I pattern
was significantly more common (P< 0.01) and the type III
pattern was significantly less frequent (P< 0.05). Interestingly,
the EOGC group had significantly lower frequent Hp infection
rate than the old GC (P< 0.05, Table 1).
Histopathology
According to Lauren’s classification, the diffuse type
(79.4%) was significantly more common in young GCs
(P< 0.01), whereas the intestinal type was significantly more
common in old GCs (62.4%) (P< 0.01). As shown in Table 1,
43.4% of young patients were significantly more frequently
diagnosed at advanced stage (pIII, P< 0.01), compared with
20.8% in old patients. In EOGCs, tumor distant metastasis
(n¼ 15) was limited to abdominal organs, mainly to the ovary
(n¼ 6), peritoneum (n¼ 4), colon (n¼ 4), and pancreas (n¼ 1).
Clinicopathological Characteristics of Familial
EOGC
Detailed family cancer history was available in all 152
patients (Table 2 and Figure 3). Thirty-eight (25%) GC cases
met the FGC diagnostic criteria, whereas the majority (n¼ 114,
75%) were classified as SGC. Among typical pedigrees of FGC,
the autosomal dominant hereditary pattern was most common.
The most common organ with cancer in the relatives was, in the
descending order, the stomach, esophagus, liver, lung, and
colorectum (Table 3). In contrast, esophageal, hepatic, and
pulmonary cancers were significantly more frequently found
in the SGC group. However, the difference in overall clinico-
pathology between the 2 groups was not statistically significant.
Differences in Clinicopathology between Very
Young (<— 30 years) and Older (31–40 years)
EOGC Patient Groups
To investigate the biological behavior of EOGCs, we
further divided the cohorts into 2 groups, according to age
(Supplementary Table 1, http://links.lww.com/MD/A718). The
very young EOGC (30 years) group, compared to the older
(31–40 years) group, was significantly more likely to have
more frequent PNI (76.3% vs 57.0%, P¼ 0.034). No other
significant differences in clinicopathology were found between
the 2 groups.
Hp Infection Status
Hp infection was detected in 51.1% of EOGC cases.
The clinicopathological difference between Hp-positive and
-negative patients was shown in Supplementary Table 2,
http://links.lww.com/MD/A719. Interestingly, the Hp infection
rate was significantly higher in the older (31–40 years, 55.1%)
GC group, Lauren’s intestinal type, and longer symptom
duration, but significantly lower in patients staged at pIII and
pIV (P¼ 0.002) and PNI (P¼ 0.001). Consequently, the survi-
val rate in patients with Hp infection was significantly higher
than those without. Univariate logistic regression analysis
showed that patient age, advanced macroscopic pattern (i.e.
local or infiltrating, ulcerative, whole gastric involvement),
Lauren’s intestinal type, larger tumor size >4.0 cm, advanced
tumor stage (cIII and cIV), pT stage, and PNI were significantly
associated with Hp infection, whereas Lauren’s intestinal type
and early pT stage (pT1 and pT2) were the independent risk
factors for Hp infection by multivariate analysis (Table 4).
Prognostic Factors for Overall Survival
In the cohort, 137 EOGC patients (90.1%) underwent
radical R0 surgical resection with curative intent. Tumor pal-
liative resection was carried out in 15 (9.9%) (R1 resection)
patients. Two EOGC patients underwent endoscopic submuco-
sal dissection with subsequent additional open surgical resec-
tion with nodal dissection because of signet-ring cell carcinoma.
One patient had severe postoperative complications with
multiple organ failure and died of extensive abdominal metas-
tasis. Of 152 EOGC patients, 42 (27.6%) died of cancer-specific
causes. Univariate analysis (Table 5) identified poor prognostic
factors including lower BMI (<18.5 kg/m2), the absence of Hp
infection, lower serum levels of albumin, higher levels of CA
72–4, CA 125, and CA 19–9, larger tumor size of>4 cm, whole
stomach involvement, advanced macroscopic patterns (type
pIII–pIV),30 palliative R1 surgical resection, advanced patho-
logic stage (pIII and pIV), LVI, PNI, and resection margin
involvement. By multivariate analysis (Table 5), independent
worse prognostic factors included higher serum levels of CA
72–4 (HR: 7.673, 95%CI: 2.475–23.791,P<0.001), higher CA
125 (HR: 3.903, 95% CI: 1.121–13.590, P¼ 0.032), positive
resection margin (HR: 11.081; 95% CI: 3.957–31.028,
P¼ 0.017), and advanced tumor stage pIII (HR: 12.851),
95% CI: 1.601–103.122, P¼ 0.016) and pIV (HR: 72.516,
95% CI: 7.750–678.516, P< 0.001). Kaplan–Meier survival
curves for EOGC patients, according to independent prognostic
factors, were exhibited in Figure 4.
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FIGURE 3. Typical pedigree of familiar gastric carcinoma patient.
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DISCUSSION
In line with previous similar investigations in other ethnic
populations,4,22,31,32 our study reveals that EOGCs in Chinese
patients treated at our hospital are also female predominant and
showmainly the diffuse histology type. Although FGC accounts
for only 25% of the EOGC cohort, there are no significant
differences in clinicopathology between FGC and SGC groups.
However, very young ( 30 years) patients have a significantly
lower Hp infection rate, but a higher PNI rate than older
patients, the findings that have not been described before.33,34
To our surprise, high serum levels of CA 72–4 and CA 125,
along with palliative resection, are identified as independent
risk factors for worse outcomes in EOGC patients, which may
be clinically useful for patient management, if confirmed
by additional clinical studies with larger samples from other
centers.35,36
EOGC is uncommon and found in only 3.2% of all GC
resections in our cohort, which is consistent with previous
studies (2–8%).15,37–39 Although the true incidence of EOGC
in China remains unknown, a recent American study, based on
the data of the National Cancer Institute’s Surveillance Epide-
miology and End Results (SEER) program in the United States,
shows a significantly increased incidence trend from 0.27 to
0.45 per 100,000 person-years for both female and male patients
aged between 25 and 39 years.40 However, that study is limited
to noncardiac GC only and carried out in a low GC risk
population. In contrast, a significantly decreased EOGC inci-
dence for male patients has been reported by Korean investi-
gators under the Population-Based Regional Cancer Registry
(PBCR) program in Korea,41 which is a high GC risk popu-
lation, as the Chinese.
In general, family cancer aggregation is more common in
EOGC patients than in older age GC groups, as also shown in
our study. In our cohort, FGC accounted for 25% of EOGCs, a
percentage similar to that reported by Umeyama et al in
Japan,6 but slightly higher than that described by investigators
from Shanghai in China9 and in Korea.15,35 Our studies show
that the EOGC tumor location is more frequent in the middle
stomach, which is consistent with that reported previously
in Chinese9 and Japanese42 studies, suggesting underlying
unique, probably hereditary, pathogenesis mechanisms that
are different from those in the proximal or distal stomach.
Nevertheless, the published data indicate an important role
of hereditary factors in tumorigenesis of EOGC in both
TABLE 3. Cancers Among the First- and Second-Degree
Relatives of Early-Onset Gastric Carcinoma Patients Between
Familial and Sporadic Groups
Cancer Site
Total
Number
(%)
First- and
Second-Degree
Relative
PFGC (%) SGC (%)
Total 145 85 60
Stomach 56 (38.6) 56 (100) 0 (0)
Esophagus 20 (13.8) 6 (30.0) 14 (70.0) 0.005
Liver 17 (11.7) 5 (29.4) 12 (70.6) 0.009
Lung 13 (9.0) 3 (23.1) 10 (76.9) 0.006
Colorectum 10 (6.9) 6 (60.0) 4 (40.0) 0.927
Pancreas 5 (3.4) 1 (20.0) 4 (80.0) 0.186
Gallbladder 3 (2.1) 3 (100) 0 0.267y
Bone 3 (2.1) 1 (33.3) 2 (66.7) 0.759
Leukemia 2 (1.4) 0 2 (100) 0.170y
Breast 2 (1.4) 1 (50.0) 1 (50.0) 1.000y
Uterus 2 (1.4) 0 2 (100) 0.170y
Nasal pharyngeal
cancer
1 (0.7) 1 (100) 0 1.000y
Melanoma 1 (0.7) 1 (100) 0 1.000y
Brain 1 (0.7) 0 1 (100) 0.414y
Kidney 1 (0.7) 0 1 (100) 0.414y
Prostate 1 (0.7) 1 (100) 0 1.000y
Bladder 1 (0.7) 0 1 (100) 0.414y
Lymphoma 1 (0.7) 0 1 (100) 0.414y
Unknown 5 (3.4) 0 5 (100) 0.011y
FGC¼ familial gastric cancer, SGC¼ sporadic gastric cancer.
x2 test. yFisher’s exact test.
TABLE 4. Univariate and Multivariate Analyses (Logistic Regression) of Clinicopathological Features in Relation to Hp Infection in
Early-Onset Gastric Cancer Patients
Univariate Analysis Multivariate Analysis
Factors Risk Ratio (95% CI) P RR (95% CI) P
Age (30 years) 1.083 (1.012–1.160) 0.021
Macroscopic type
Early GC
Advanced GC 0.296 (0.121–0.724) 0.008
Tumor size (>4.0 cm) 0.862 (0.758–0.981) 0.024
Lauren’s classification
Diffuse/mixed
Intestinal 12.868 (1.608–102.969) 0.016 18.896 (1.693–210.871) 0.017
Perineural invasion 0.303 (0.147–0.625) 0.001
Clinical tumor stage
IþII
IIIþIV 0.476 (0.240–0.941) 0.033
Advanced pT stage (pT3 and pT4) 0.207 (0.096–0.445) <0.001 0.044 (0.005–0.382) 0.005
CI¼ confidence interval, GC¼ gastric carcinoma, RR¼ risk ratio.
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Western and Asian populations. Compared with SGC, the
FGC group does show more frequent esophageal, liver and
lung cancers in the proband first- and second-degree relatives.
Interestingly, those cancers rank the highest in incidence
among other organ types of cancer in the general population
in China,3 suggesting a hereditary component(s) in those
cancers. A recent genomic study43 points out that germline
mutation of the CDH1, CTNNA1, or MAP3K6 genes may
be involved in the tumorigenesis of some FGCs. Further
investigations are needed to reveal genomic mechanisms of
hereditary GC in Chinese patients. In contrast in the SGC
group, lung and liver, but not esophageal, cancers are pre-
dominant, a finding consistent with the data from the Chinese
National Central Cancer Registry (NCCR) published in 2011.3
Apparently, EOGC in the SGC group may be part of common
cancer syndromes but the hereditary relationship may exist
between esophageal and gastric cancers in the Chinese popu-
lation, as alluded by the most recent meta-analysis of GC
genomics.44
GC is more common in men with a male/female ratio
ranging from 1.62:1 to 2:1.45,46 However, most surveys on
EOGC, including our own, have shown a female dominance
with the male/female ratio ranging from 0.64:1 to 0.87:1.15,35,47
This observation suggests the potential role of estrogen in
EOGC pathogenesis. According to a prospective study on
Spanish women,48 the risk of GC increased in women who
had oophorectomy, indicating the protective effect of estrogen
against GC development, which has been confirmed by 2 large-
scale studies in Japan49 and in China.50 Further investigation to
illustrate molecular mechanisms by which estrogen plays in
EOGC tumorigenesis is needed.
Hp infection has been proven to be carcinogenic in GC
development but conveys a favorable survival outcome in GC
patients with Hp infection, compared to those without Hp
infection,51 which is also our experience in EOGC. Moreover,
we show that very young ( 30 years) GC patients are less
likely to be infected withHp and less exposure to environmental
toxins,52 suggesting that hereditary factors may be of more
TABLE 5. Uni- and Multivariate Analyses (Cox Regression) on Prognosis of EOGC Patients
Univariate Analysis Multivariate Analysis
Factors RR (95% CI) P RR (95% CI) P
Female 1.322 (0.692–2.528) 0.397
Age (30 y) 1.139 (0.570–2.274) 0.713
Positive family history 0.745 (0.355–1.561) 0.435
Higher body mass index 0.193 (0.096–0.391) <0.001
Positive Hp infection 0.460 (0.233–0.909) 0.026
Laboratory findings
Higher albumin level 0.362 (0.137–0.961) 0.041
Higher CA 72–4 3.287 (1.401–7.716) 0.006 7.673 (2.475–23.791) <0.001
Higher CA 125 3.276 (1.222–8.781) 0.018 3.903 (1.121–13.590) 0.032
Higher CA 19–9 3.863 (1.724–8.653) 0.001
Larger tumor size (cm) 1.453 (1.314–1.608) <0.001
Tumor location
Proximal
Middle 0.421 (0.132–1.343) 0.144
Distal 0.624 (0.212–1.837) 0.392
Whole gastric 3.671 (1.078–12.501) 0.037
Macroscopic type

Early GC
Advanced GC 31.298 (1.467–667.893) 0.027
Surgical resection
Radical
Palliative 6.942 (3.381–14.253) <0.001
Lauren’s classification
Diffuse (and mixed)
Intestinal 0.186 (0.025–1.356) 0.097
Positive resection Margin 6.679 (3.329–13.398) <0.001 11.081 (3.957–31.028) <0.001
Staging (AJCC 7)
I
II 2.515 (0.228–27.771) 0.452
III 26.814 (3.626–198.293) 0.001 12.851 (1.601–103.122) 0.016
IV 76.699 (9.603–612.577) <0.001 72.516 (7.750–678.516) <0.001
Lymphovascular invasion 10.005 (3.540–28.281) <0.001
Perineural invasion 8.955 (3.152–25.435) <0.001
AJCC¼ American Joint Committee on Cancer, CI¼ confidence interval, EOGC¼ early-onset gastric cancer, GC¼ gastric carcinoma, RR¼ risk
ratio.
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importance than Hp infection in tumorigenesis of EOGC. We
showed that the absence of Hp infection was associated with a
shorter symptom duration, more advanced tumor stage, and
more frequent PNI, which are consistent with those reported in
1995 by a research group from Taiwan.51 Lee et al first reported
thatHp seropositive GC patients with localized Borrmann types
showed better survival than Hp-negative counterparts.51
Recently, Hp infection was found to be an independent prog-
nostic factor for relapse-free survival and overall survival.53,54
The immune response activated by Hp infection could lead to
genesis of gastric adenocarcinoma (activation of Th17 path-
way),55 but meanwhile can also modulate antitumor immu-
nity.54 The molecular interplay between Hp infection and host
genetic vulnerability is essential for illustration of EOGC
pathogenesis mechanism.
The postresection survival of EOGC patients remains
elusive.56 In our study, the 5-year survival rate in EOGC
patients was 64%, which is much higher than that reported
by Korean and Japanese investigators.9,35 The discrepancy may
be related to several factors. First, we included only the patients
who underwent surgical or endoscopic resection with additional
surgical nodal dissection. This indirectly suggests that if young
GC patients diagnosed at a resectable stage, the prognosis
would be favorable. Second, most patients in our cohort have
undergone radical resection that demonstrates a significant
survival advantage than those with palliative surgery only.
A major limitation of our study is the retrospective study
design. As a result, not all cases have a complete dataset for
analysis. In addition, we rely on patient self-reporting family
history, which might have contributed to under-reporting of
second-degree positive family history and under-diagnosed
FGC. Although those variables are difficult to be controlled
in the present study, we are currently conducting a robust
prospective clinical investigation with a major focus on her-
editary GC diseases at our center.
CONCLUSION
We show that family aggregation in GC is more common
in EOGC patients but FGC patients have clinicopathological
features similar to SGC patients; early detection of high serum
levels of CA 72–4 and CA 125 and subsequent radical, rather
than palliative, resection could improve survival outcomes,
especially for those with positive family history. Further geno-
mic studies of EOGC especially FGC may help reveal molecu-
lar tumorigenesis mechanisms to provide EOGC patients with
optimal individualized precision management strategy.
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